PROS1 and AL amyloidosis: Two landmark studies have advanced the development and clinical application of EXENT‐MS, a MALDI‐TOF‐MS‐based technology for the detection and quantification of monoclonal proteins (M‐proteins), highlighting its transformative potential in the noninvasive monitoring of multiple myeloma.